Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-EN Version v1-EN
Language English English
Date Updated 2019-06-12 2019-04-01
Drug Identification Number 02328496 02328496
Brand name SANDOZ IRBESARTAN SANDOZ IRBESARTAN
Common or Proper name IRBESARTAN IRBESARTAN
Company Name SANDOZ CANADA INCORPORATED SANDOZ CANADA INCORPORATED
Ingredients IRBESARTAN IRBESARTAN
Strength(s) 300MG 300MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 100
ATC code C09CA C09CA
ATC description ANGIOTENSIN II ANTAGONISTS, PLAIN ANGIOTENSIN II ANTAGONISTS, PLAIN
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date
Actual start date 2018-11-05 2018-11-05
Estimated end date 2019-09-30 2019-06-03
Actual end date
Shortage status Actual shortage Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments